



Tree of life: endothelial cell in norm and disease, the good guy is a partner in crime!

Basheer Abdullah Marzoog

National Research Mordovia State University, Saransk, Mordovia

Abstract: Undeniably, endothelial cells (EC) contribute to the maintenance of the homeostasis of the organism through modulating cellular physiology, including signaling pathways, through the release of highly active molecules as well as the response to a myriad of extrinsic and intrinsic signaling factors. Review the data from the current literature on the EC role in norm and disease. Endothelium maintains a precise balance between the released molecules, where EC dysfunction arises when the endothelium actions shift toward vasoconstriction, the proinflammatory, prothrombic properties after the alteration of nitric oxide (NO) production and oxidative stress. The functions of the EC are regulated by the negative/positive feedback from the organism, through EC surface receptors, and the crosstalk between NO, adrenergic receptors, and oxidative stress. More than a hundred substances can interact with EC. The EC dysfunction is a hallmark in the emergence and progression of vascular-related pathologies. The paper concisely reviews recent advances in EC (patho) physiology. Grasping EC physiology is crucial to gauge their potential clinical utility and optimize the current therapies as well as to establish novel nanotherapeutic molecular targets include; endothelial receptors, cell adhesion molecules, integrins, signaling pathways, enzymes; peptidases.

Key words: Endothelium; Endothelial cells; Regeneration; Homeostasis; Nitric oxide


Received September 29, 2022; Revised January 20, 2023; Accepted January 25, 2023

Introduction

Tremendous advances have been made in vascular biology in recent years. Physiologically, the endothelium comprises highly specialized cells that line the blood and lymphatic vessels, weigh 1 kg and build approximately 400 m² in an adult person that maintains approximately 60,000 miles of blood vessels. Endothelial cells (EC) performs a wide range of crucial metabolic homeostatic activities to maintain a balance between aggression and protection factors by responding to extrinsic and intrinsic signals and releasing specific active molecules, as well as remodeling signaling pathways

[1-3]. Firstly identified molecules were antithrombosis and hemostatic agents (protein c and s, thrombomodulin [TM], calmodulin [CaM], tissue-type plasminogen activator, plasminogen activator inhibitor type I, platelet activating factor, von Willebrand factor [vWF] that stay in Weibel-Palade bodies), pro and anti-inflammatory molecules (E-selectin, P-selectin, ICAM-1, VCAM-1, PECAM-1, Decay Acceleration Factor, CD59), and vasoactive substances (endothelin 1 [ET 1], thromboxane A₂, superoxide, prostaglandin F_{2a}, prostacyclin I₂, endothelium-derived hyperpolarising factor, nitric oxide [NO], urotensin, C type natriuretic peptide [CNP], adrenomedullin, adenosine, purines, reactive oxygen species, H₂S, angiotensin II, bradykinin) [4-8]. A couple of these molecules are released under the effect of extrinsic factors (cytokines) such as urokinase-type plasminogen activator. Interestingly, the EC release many molecules and simultaneously express receptors for them, which makes the endothelium behave like autocrine cells as well as paracrine.

Corresponding author:

Basheer Abdullah Marzoog 

National Research Mordovia State University, Saransk 430005, Mordovia

E-mail: marzug@mail.ru

Copyright © 2023. Anatomy & Cell Biology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

The self-regulation mechanisms various from organ to other, according to the requirement and the nature of the presented tissue, therefore the bearing capabilities differ in each organ and this probably shows the susceptibility of endothelial dysfunction variation in different tissues and why usually endothelial dysfunction is characterized for some tissues and not for others [9]. On the other hand, these distinct morpho-physiological variations in the EC are probably can be used to enhance the selectivity of the endothelium-delivered drug. For example, EC in the branching points express different genes than other areas [10]. Besides, caveolae are extensively expressed in cardiac and pulmonary EC, whereas caveolae are absent in cerebral EC. Also, endothelial cell protein C receptor (EPCR) is enriched in large vessels and has low expression in the smaller vessels [8].

Furthermore, EC can modify their metabolic activities, probably, through modulation of active substance releasing, according to the triggered endothelial plasma membrane receptor [11-13]. Usually, the transient receptor potential (TRP) and G-coupled-protein receptor play a leading role in triggering the intracellular signaling cascade, later activate specific Ca^{+2} channels or K^{+} channels as well as probably

promote specific gene expression or repressions such as pro-inflammatory genes that encode for cytokines, via activating the nuclear factor- κ B or mitogen-activated protein kinase pathways [14, 15]. Moreover, the EC receptors perform recognition and sensation activity for IL6, IL8, H2S, TNF-related activation protein; E-selectin, P-selectin, ICAM-1, VCAM-1, PECAM-1; D-Dimer, vWF, TF, PAT-1; iNOS, nitrotyrosine; PECAM-1, MadCAM-1, JAM-1, Cav-1; CECs, EMPs; CRP, PTX3 via sensor systems including glycocalyx, caveolae, cytoskeleton and integrins interconnected with components of extracellular matrix and intercellular junctions; in particular, PECAM-1 (Table 1) [5, 16]. The G-coupled-protein receptor and Src-dependent tyrosine kinase, endothelial nitric oxide synthetase (eNOS), or ion channel signaling pathway of the EC are strictly related to the caveolin-1, micro-particle protein embedded in an omega-shaped cholesterol and glycosphingolipid rich caveolae, 15% of the EC membrane [6]. The topography of the EC gives them a critical physiological and pathological role in the progression of the diseases since EC sense all changes in the organism via direct interaction with the blood biomarkers of the disease. Therefore, the endothelium plays a role in the promotion of pathogenesis.

Table 1. Vascular EC surface receptors and their agonist

Vasoconstriction		Vasorelaxation	Angiogenic
TGF- β receptor (endoglin)	ET-1 receptor (ET-B)		Vascular endothelial growth factor A, B
Thromboxane A2 receptor (T)	ADP, ATP receptor (P)		Vascular endothelial growth factor receptor 1, 2, 3
Angiotensin II receptor (AT1)	Bradykinin receptor (B2)		Angiopoietin-1 receptor (binding ANGPT1, ANGPT2 and ANGPT, angiogenic)
Serotonin receptor (51)	Ach receptor (M3)		Integrin alpha-L receptor (binds ICAM1, ICAM2, ICAM3, and ICAM4)
Ach receptor (M5)	G protein-coupled receptor 68		Plasminogen activator inhibitor 1, 2 (Inhibits urokinase-type plasminogen activator)
α 2-adrenergic endothelial receptor	Histamine H1 receptor		Neuropilin-2 (Cytokine binding, semaphorins)
Prostaglandin E2 (Gs-coupled receptors)	Sphingosine-1-phosphate receptor 1		Thymidine phosphorylase (angiogenic)
	VEGFR2, peroxisome proliferator-activated receptor delta H2S		E-selectin (binding PSGL1, mediates immunoadhesion)
	Natriuretic peptide receptor A, B, and C		Receptor-type tyrosine-protein phosphatase beta (angiogenic)
	β 2-adrenergic endothelial receptor		Anthrax toxin receptor 1 (binding with extracellular matrix proteins, angiogenic)
			Platelet-derived growth factor receptor alpha and beta (VEGF binding)
			Receptor-type tyrosine-protein kinase FLT3 (binding cytokine FLT3LG)
			Cadherin-5 (Receptor binding)
			Placenta growth factor (heparin-binding, angiogenic)
			Glucose-6-phosphate isomerase (angiogenic)
			Nitric oxide synthase, endothelial (Tetrahydrobiopterin binding, angiogenic)

Activation of the stated receptors induces the respective vasoactivity, including constriction, dilation, and angiogenesis. Ach, acetylcholine; VEGFR2, vascular endothelial growth factor receptor 2, M, muscarinic. Source from [17-27].

Indeed, many of these biomarkers are of inflammatory response to protect against the invaders but unfortunately, usually, accompanied by self-damage. However, normally, the advantages weigh more than self-damage. It is extremely important that the endothelium is the executive representative of the cardiopulmonary system on the tissue side.

The paper aimed to analyze the recent advances in the role of blood EC in physiopathology and prescribe these functions; namely, control of vascular permeability, adhesiveness, contractility, and formation of new vessels (angiogenesis), detection of mechanical forces related to blood flow and vessel contraction, the interaction of blood components with vessels and underlying tissues, blood metabolism, clotting and fluidity, and gas exchange.

Review

Vascular tone regulation function

ET 1, Thromboxane A2, Superoxide

ET 1 is a high-yield vasoactive substance that is primarily synthesized by the EC of the blood and lymphatic trees [28]. However, ET 1 effects are not limited to the vascular tree 2 and have a high affinity to ET_A, ET_B, and ET_C receptors, >60% of endothelin heart receptors are ET_A and vice versa in the lung, liver, and kidney, predominant ET_B [29]. The presence of various isotypes of endothelin receptors makes ET 1 a universal active substance, ET 1 receptors are present in the cardiovascular system (endothelium, VSMCs, cardiomyocytes), urinary system (renal medulla), nervous system (neurons), immune system and skin (macrophages, leukocytes, mast cells, Kupffer cells), respiratory system (tracheal epithelium, airway epithelial cells), other tissues and cells (fibroblasts, hepatic sinusoids) [30, 31]. Physiologically, four types of endothelin receptors are present in the organism (ET_A, ET_{B1}, ET_{B2}, ET_C); however, only two of them have been well studied. In fact, endothelial-endothelin production is enhanced by the activation of activator protein-1, GATA-2, smad, hypoxia-inducible factor-1, and NF- κ B transcription factors [30, 32]. Normally, each organ has a higher concentration of specific isotype of the endothelin receptor and accordingly the endothelial of these organs produce the more required endothelin subtype. For instance, the kidney EC, mostly synthesize ET₁ and express ET_B receptors, to scavenge ET-1 from the plasma and reduce salt and water reabsorption in renal tubules [29]. Endothelin contributes to the extracel-

lular matrix production, and proliferation and migration on vascular EC, vascular smooth muscle cells, fibroblasts, and macrophages/immune cells [33]. Activation of endothelin receptor-B (ET-B) on the EC leads to vasodilation by releasing specific vasodilator mediators and oppositely on the vascular smooth muscle cells where ET-B receptor activation results in vasoconstriction. The ET-A receptor is specific for vascular smooth muscle cells [34]. The biosynthesis of endothelin 1 by the EC is promoted by hormones (epinephrine, cortisol, angiotensin II, vasopressin, insulin), xenobiotics (A23187, cyclosporine), peptides (cytokines; IL-1, TGF- β , endotoxin, ET 1), psychochemical stimuli (hypoxia, shear stress; low), blood components (thrombin, glucose, oxidised LDL) as well as by inhibition of prostacyclin, NO, ANP, BNP, CNP, heparin, shear stress; high [30, 35]. The ET 1 degraded by lysosomal cathepsin A and its inactivation disorders lead to elevation of arterial blood pressure. In the kidney, ET1 induces sodium excretion (diuresis), exerts its effect through ET-B receptors on the epithelial cells of the collecting duct [29]. Several clinical data showed a relationship between ET-1 and the pathogenesis of pulmonary arterial hypertension, vasculopathy, and fibrosis of the skin, lungs, and other organs in systemic sclerosis as well as the potential therapeutic role for endothelin antagonists in these conditions in systemic sclerosis.

Auxiliary vasoconstrictor substances are thromboxane A2, superoxide, their release is usually inflammation-dependent. Both exert their effect in an auto-paracrine manner on their specific EC receptors. However, their effects and receptors are not limited to the ECs, but they can interact directly with VSMCs and induce extra actions (Table 2).

NO

Normally, in the state of inflammation or high blood pressure, the EC shrink, while VSMCs relax to increase interendothelial space and vascular diameter, which is accompanied by hyperpermeability and lower blood pressure. Prostacyclin I2, NO, urotensin, CNP, adrenomedullin, adenosine, purines, reactive oxygen species, and H2S all are vasodilator molecules. NO is a free nitrogen radical released as a byproduct of several cellular activities, including the electron transport chain and under hypoxia and anoxia. Several cells release NO under unfavorable conditions including EC. NO is the most active vasodilator substance and controls the synthesis and activity of vasodilator molecules in the EC. Suggesting, a balance is kept between the endogenous NO production and ET-1/ETA activity to maintain the systematic

Table 2. Endothelial released substances and their target receptors as well as their effect

Endothelium released substance	Receptor	Effect
Endothelin 1	ET _A	VSMCs contraction
	ET _B	VSMCs relaxation
	ET _C	
Prostacyclin I ₂	G _s -protein-coupled receptor (prostacyclin I ₂)	Relaxing the VSMCs anti-aggregation
Prostacyclin F2 α	TP receptors (prostacyclin F2 α)	SM contraction
Endoperoxides	TP receptors (endoperoxide)	VSMCs contraction
Nitric oxide	G-protein-coupled receptor (nitric oxide)	Relaxing the VSMCs, Inhibits endothelium-derived hyperpolarization action, anti-aggregation
Endothelium-derived hyperpolarizing factor (H ₂ O ₂)	G-protein-coupled receptor (H ₂ O ₂)	VSMCs hyperpolarization
Protein C	Thrombomodulin	Anti-inflammatory neuroprotective and neurogenesis, protection of the vascular endothelium from apoptosis and promoting endothelial barrier function
	G-protein-coupled receptor	
	protease-activated receptor 1	
	Endothelial cell protein C receptor (EPCR)	
Thromboxane A2	Thromboxane A2 receptor, G-protein-coupled receptor (1A, 1B, 3A, and 6)	VSMCs depolarization
Superoxide	G-protein-coupled receptor (superoxide)	VSMCs depolarization
Angiotensin II	Angiotensin II receptor 1	VSMCs hyperpolarization
Bradykinin	Bradykinin receptor	VSMCs hyperpolarization
vWF	Ang-2/Tie-2/VEGFR-2	Angiogenesis
	α v β 3 integrin	Anti-angiogenesis
Gal-3 (molecule of vWF)	VEGFR2	Proangiogenic activity
	integrin α v β 3	
Adenosine	ADORA2A	Enhance glycolysis, inflammation
	Adora α 1, Adora α 2b	Angiogenic
CNP	Global natriuretic peptide receptor (NPR)-B, C	Angiogenic, cytoprotective, VSMCs hyperpolarization
Adrenomedullin	Adrenomedullin receptor (G _s -coupled receptor)	Increases NO releasing,
		Block RAAS
		Angiogenic
Urotensin II	G-protein-coupled receptor (Urotensin II receptor)	Angiogenic, VSMCs relaxation
H2S	Unknown (include PI3K/Akt pathway)	Angiogenic, VSMCs relaxation
PAF	PAFR (G _{i,q}) transcripts 1 (leukocytes, activated eosinophils) and 2 (Heart, lungs, spleen, kidney)	Mediating cell-cell interaction, VSMCs relaxation,
		↑ glycogenolysis, ↑ leukotrienes D4 and C4,
		↑ response to convulsant stimuli and ischemia, heart rate and contractility modifying,
		↑ glomerular filtration rate, required for oocyte maturation and successful outcomes of pregnancy
Purines	19 isotypes; G _{i,s,q} , P2Y, P2X	Vasomotor regulation

vWF, von Willebrand factor; VEGFR, vascular endothelial growth factor receptor; RAAS, renin-angiotensin-aldosterone system; VSMC, vascular smooth muscle cell. Data from [38, 39, 47-49, 74-77].

vascular tone. Endothelial-derived NO release can inhibit the effect of adrenergic innervation on vascular smooth muscle cells [36]. Therefore, the sympathetic tone is predominant in the case of endothelial dysfunction. Currently, it is widely accepted that all adrenergic receptors (β 1, 2, 3) contribute to the regulation of vascular tone. However, adrenergic receptors exert their effect on the vessels through the regulation of NO synthase activity, suggesting a NO-dependent vasomotor regulation. Furthermore, the β 2 receptor is the predominant vasodilator in large vessels, α 2 vasoconstrictor in the periph-

eral vessels, while β 3 was found to enhance eNOS activity in the cardiac chambers and coronary microcirculation, indicating a vasoprotective role [37]. β 2 expression is required to sustain a sufficient NO plasma level which is required for maintaining vascular homeostasis, whereas β 2 gene silencing *in vitro* induced oxidative stress and impaired endothelial NO production, confirmed by antioxidant administration superoxide dismutase, reversed the vasoconstriction [37]. The stimulation of the β 3 receptor induces angiogenesis. Accumulating evidence, hydrogen peroxide (H₂O₂) is directly

involved in vasorelaxation, whereas, endothelium-dependent relaxation (EDR) involves both pertussis toxin-sensitive G_i include; responses to α_2 -adrenergic agonists, serotonin, and thrombin, and pertussis toxin-insensitive G_q include; adenosine diphosphate and bradykinin coupling proteins. EDR is promoted by newly discovered stimulators such as insulin, adiponectin [38].

Auxiliary, EC respond to high shear stress by releasing peptide hormone called adrenomedullin, due to activation of the endothelial mechanosensitive cation channel PIEZO1, which induces endothelial NO synthesis by binding of adrenomedullin to its G_s -coupled receptor protein in EC [39]. PIEZO1 activation induces G_q /G11-coupled purinergic P2Y2 receptor activation via an ATP-dependent manner. This required to phosphorylate eNOS at serine 1177/633 which is involved PECAM-1, VE-cadherin, and vascular endothelial growth factor receptor-2 (VEGFR-2)/VEGFR-3 mechanosensitive complex activation [39]. Therefore, adrenomedullin is a marker of hypertension and a guide for the treatment of sepsis and acute heart failure since it shows the severity of endothelial dysfunction including endothelial barrier function disturbance. Adrenomedullin is degraded by neprilysin which is blocked by valsartan, after 22 minutes of lifelong, adrenomedullin is degraded or cleared through binding to its cell surface receptor and internalization then degradation [40]. Finally, NO itself, under certain conditions such as hypoxia, can induce biased activation of soluble guanylyl cyclase promoting the synthesis of cyclic inosine monophosphate instead of cGMP and enhancing contraction rather than relaxation of the beneath VSMCs.

Angiogenesis function

Angiogenesis is a complex process that requires the co-operation of various cell types through signaling exchange between these cell types, aimed at forming new blood vessels from old ones, vascular stem cells, or EC. Angiogenesis or lymphangiogenesis are critical in the progression of many diseases including tumor metastasis and ischemic heart disease [41]. Indeed, EC proliferation-induced-angiogenesis is triggered by several growth factors that are released by the underlying matrix including; FGF-2, TGF- β , TNF- α , IGF-1, and VEGF. However, VEGFR-2 activation, separately able to induce EC proliferation as well as migratory and sprouting activity and to help promote EC to form tubule-like structures. The VEGF combination with chemokines such as angiopoietin-1 and integrins can determine the neovessels'

destination by ephrins migration regulation. The VEGF is required for the initiation of angiogenesis and the formation of immature vessels, while Ang1 and ephrinB2 are responsible for the maturation of initial immature blood vessels. Furthermore, Ang1 expression probably is required for the maintenance of vasculature cells' identity. On the curbing of EC proliferation is mediated by thrombospondin-1, canstatin, arrestin, tumstatin, angiostatin, and endostatin which are also released by the beneath matrix [6]. Also, the receptor for the vascular endothelial protein tyrosine phosphatase is allocated on the endothelial cell, involved in angiogenesis regulation and membrane fluidity, as well as homeostasis maintaining of the inflamed area through the regulation of the tyrosine kinase receptor Tie-2 and VE-cadherin substrates regulation [42]. Undoubtedly, EC are also involved in vascularization regulation of vascularization.

The endothelial released molecules are also involved in the regulation of angiogenesis such as activated protein c (APC) and vWF [43]. More recently, novel investigations have shown that suppression of vWF expression increases endothelial proliferation, migration, and angiogenesis through binding to integrin $\alpha v \beta 3$, and components of Weibel-Palade bodies, such as angiopoietin-2 and galectin-3, whose storage is regulated by vWF, whereas endothelial protein C receptor probably suggests hematopoietic stem cells dormancy and multilineage reconstitution potential [44, 45]. Angiopoietin Ang2 (ANGPT2) binds to tyrosine kinase Tie2 and destabilize blood vessels and synergize with VEGF to promote angiogenesis [46]. Additionally, Gal-3, via the interaction with VEGFR-2 and integrin $\alpha v \beta 3$ endothelial cell vWF domains induces angiogenesis, whereas, Gal-3 inhibition, reduces proangiogenesis activity [47]. The Gal-3 regulates cell-cell adhesion which is probably an important step for proangiogenesis [48]. Recent clinical data suggest that an imbalance between Ang1 and Ang2 activity probably underlying the development of the vascular lesions, and maintaining a balance between these growth factors is required for healthy vasculature [49].

Anticoagulation function

Protein c and s are primary anticoagulant peptides synthesized by the liver and platelet as well as EC. Protein c activation requires thrombin-thrombomodulin complex formation on the EC surface, involves proteolysis at Arg169 in EPCR-bound protein c EPCR [50, 51]. Once protein c has been activated, protein s synergistically with calcium and

phospholipids cleavage specific arginine polypeptide of proaccelerin and activated antihemophilic factors to inactivate coagulation and promote fibrinolysis by inhibition of tenase and prothrombinase complex [50, 52]. The APC activities are enhanced by protein S, high-density lipoprotein, and glucosylceramide [53]. Furthermore, in animal models, APC induces ERK1/2 (extracellular signal-regulated kinase) during EC proliferation and angiogenesis to promote early growth response factor-1 gene expression through PAR1/S1P1-dependent but EPCR-independent mechanisms solely inhibit TNF α -induced apoptosis in EC [51]. Moreover, in rheumatoid synovial fibroblasts, APC decreases the TNF α -induced phosphorylation of p38 MAPK and JNK [54]. Deficiency of protein s and or c results in DIC syndrome, while activated PC exerts a neuroprotective and neurogenesis effect through G-protein-coupled receptor, protease-activated receptor 1 (PAR1), PAR3, and EPCR that produce signaling at Arg46 site (biased signaling) [53]. The APC binds to EPCR and can cleave PAR-1 and PAR-3, which induce β -arrestin-2-biased PAR1 signaling that results in protection of the vascular endothelium from apoptosis while promoting barrier function. APC reduces the release of neutrophil extracellular trap release [55].

TM is a receptor on the surface of blood and lymphatic vessels thrombin EC, but not only in EC, consisting of 5 domains, each of which has a role in norm and pathology [56]. Thrombomodulin regulates coagulation activity and the release of inflammatory molecules, as well as EC migration via fibronectin and ezrin. Besides, its cytoprotective effects interfere with the nuclear translocation of NF- κ B and activation of AP-1 [51, 56, 57]. In murine aortic EC, the interaction of the EGF5 domain of TM with G-protein coupled receptor 15 promotes angiogenesis and cell survival through activation of ERK and BCL-2 pathway, suggesting a cytoprotective and angiogenic role of TM on EC [58]. Moreover, endothelial CD39/NTPDase-1 poses an anticoagulant effect by degrading the platelet agonist ADP. TM modulates the duration of pERK nuclear retention and cell proliferation in response to inflammatory stimuli. TM enhances smooth muscle proliferation by activating the ERK pathway through the EGFR axis that negatively affects the growth arrest-specific gene 6, whereas, TM knockdown causes smooth muscle calcification in animal models [59]. Low TM expression by the EC is probably correlated with atherosclerosis development, via the activation of p38 and JNK pathways, where the oxidized low-density lipoprotein reduces the levels of nuclear transcription

factors RAR β , RXR α , Sp1, and Sp3 and their binding to TM promoter [51].

Hemostatic function

When the continuity of endothelium is disrupted or the EC are glycosylated, the coagulation cascade is initiated. EC play a significantly crucial role in maintaining an average level of coagulability, not hyper or hypo clotting. This feature is achieved through the balance between the endothelial released hemostatic factors and the expression of pro and anticoagulant cell surface receptors. In favor of clot formation, EC induce the expression of procoagulant and suppress the expression of anticoagulant factors. Where TNF reduces the formation of TM, endothelial anticoagulant cofactor, and induces procoagulant mechanisms. EC release tissue-type plasminogen activator, plasminogen activator inhibitor type I, platelet activating factor, and vWF into plasma. Exposure to phosphatidylserine induces the release and binding of vWF to collagen fibers and subsequent platelet adhesion to vWF through GP Ib. oxidative stress improves the adhesiveness of vWF, auto association of vWF is regulated primarily by ADAMTS13 protease and is influenced by the level of LDL and HDL, as well as thrombospondin-1 [60, 61]. The arrest by the EC was firstly described in 1882 by Giulio Bizzozzero, but later on, appeared that leukocytes roll on the endothelial surface as a secondary phenomenon for coagulation.

Barrier function

The maintenance of transport between the bloodstream and tissues is carried out by EC. Usually, EC perform transcellular (intracellular) or paracellular (intercellular) transport for the fluids, molecules, and leukocytes, paracellular is the dominant form. Intracellular transport requires the formation of caveolae and, through cellular endocytosis, the transported material is internalised, then the intracellular cytoskeleton leads it from the luminal to the abluminal side and in the opposite direction. However, intercellular transport is primarily through specific intercellular tight junctions (e.g., occludins associated with ZO-1, ZO-2, and cingulin proteins) or gap junctions, VE-cadherins (intracellular cytoplasmic proteins and catenins connected to the actin-based microfilament system) [19]. The rearrangement of cadherins and occludins is required to regulate permeability. To note, the VE-cadherins functionality is regulated by small molecules of GTPases that belong to the Rho family, protein phosphorylation, and through interaction with

other transmembrane proteins. Several molecules that affect the transport intensity of intercellular transport include; physical forces (e.g., fluid shear stress) and biological mediators (VEGF, FGF, Angiopoietin-1, histamine, sphingosine-1-phosphate) as well as the balance of adhesive forces between EC and between cells and the extracellular matrix and contractile forces generated by the actomyosin system. The loss of barrier function usually arises after disturbance in the regulation mechanisms of the trans or intercellular transport. For instance, under the state of inflammation, the high level of inflammatory mediators in particular histamines induces the intercellular transport of macro and microparticles from the bloodstream to the plasma that results in edema [19].

EC surface receptors

TGF- β receptor (Endoglin)

Endoglin is a TGF- β receptor that positively regulates ALK-1 signaling to Smad1, 5, and 8 but negatively regulates ALK-5-induced Smad2 and Smad3 pathways in EC. ALK-1-mediated activation of Smad1, 5, and 8 EC require the phosphorylation of endoglin in Ser646 and Ser649 by T β RI. The (L)-endoglin comprises a long cytoplasmic tail of 47 amino acid residues, while (S)-endoglin with a short cytoplasmic tail of only 14 amino acid residues. Enhancement of signaling through ALK-1 requires L-endoglin to activate Id1 expression [62]. Whereas, signaling via ALK-5 requires S-endoglin to induce expression of the plasminogen activator inhibitor-1 (PAI-1). The PDZ-binding motif of the cytoplasmic tail of L-endoglin interacts with GAIP interacting

protein, carboxyl terminus (GIPC), a scaffolding protein that controls the cell-surface receptor expression and trafficking [62]. When TGF- β -independent interacts with endoglin, GIPC induces phosphorylation of Smad1, 5, and 8 as well as promotes cell-surface retention of endoglin. Furthermore, endoglin binds bone morphogenetic proteins and enhances their signaling via Smad1, 5, and 8. Pathophysiologically, endoglin gene results in deleterious defects in the cardiovascular system, whereas homozygous endoglin gene silencing results in hereditary hemorrhagic telangiectasia type I [62]. Elevation of endoglin is found in preeclampsia [56].

Thromboxane A2 receptor (TPr)

Thromboxane is well known as a vasoconstrictor, through the regulation of endothelial NO synthetase activity. TPr antagonist leads to decrease phosphorylation of eNOS at Ser1177 and Akt at Ser473. Whereas, TPr activation enhances reduction of the Rho-associated kinase- phosphatase and tension homolog deleted on chromosome 10-Akt-eNOS axis, suggesting TPr role in endothelial dysfunction [63]. TPr is involved in the impairment of endothelial function via reduction of NO synthesis and decreased intercellular (EC) gap junction, in turn, this contributes to the development of atherosclerosis and diabetes mellitus as well as hypertension [64].

Angiotensin II receptor (AT1)

Not surprising that the EC poses receptors for the angiotensin II, exerts its effect through the G_q receptor signaling cascade, believed that angiotensin regulates the release of




Fig. 1. EC surface receptors and released molecules. The heterogeneity of the recognized and released molecules by the EC makes them difficult for selective therapeutic targets. In addition, EC regulate and modulate several physiological processes as well as involvement in the pathogenesis of various diseases. EC, endothelial cells; vWF, von Willebrand factor; VEGF, vascular endothelial growth factor.

vasodilator substances from the EC. Furthermore, angiotensin reduces EC growth and regulates fibrinolysis through the AT2 receptor. Recent findings concluded a direct relationship between angiotensin II receptor type 1 and EC dysfunction through reduction of the endothelial NO synthase phosphorylation via AT 1 R Nox/ROS/PP2A axis, confirmed by AT1 receptor antagonists administration that normalized the NO level via blocking phosphorylation of PP2Ac Tyr307 as well as proved the role of AT-II by knockdown down the p22phox gene, also decreases the phosphorylation of PP2Ac Tyr307 [65].

Serotonin receptor (51)

The EC do pose a cell surface receptor for the serotonin; 1A, 1B, 3A, and 6. A recent investigation suggested an inhibitory role for these receptors, where 1A, 1B, receptors agonist reduced transendothelial cell migration, particularly, allergy-inducing leukocytes [66]. However, EC modify the serotonin-vascular tone activity via regulating the content of serotonin in the vascular bed. Monoamine oxidase type 1 is present in the EC that are directly related to the regulation of the vascular smooth muscle cells.

Acetylcholine receptor (M3,5)

Recent data were showing that each organ's EC has its isotype of the muscarinic (M) receptor, however, the M5 receptor approximately is expressed in all EC. The activation of the M3 receptor in healthy endothelium is responsible for vasodilation and oppositely; vasoconstriction in dysfunctional EC [67]. M1 receptors that have been found in cerebral microcirculatory endothelial cells (CMEC) have a relatively low functionality, whereas, highly expressed M3 and M4 receptors [68]. However, the study concluded that all M subtype receptors are expressed by CMECs, particularly in brain vessels and especially M3>M2>M4>M1>M5. This adds more complexity to the surface-expressed receptors of the EC in various organs, probably the same receptors present in the whole vascular tree or organ-specific!

More recently, new data have explained the role of acetylcholine released by the endothelial cell (ACh) in the flow-mediated vasorelaxation, suggesting a stimulatory effect for ACh in calcium channels to release internally stored calcium and induce NO release that leads to vasorelaxation through the previously cAMP pathway [69]. However, ACh production by the EC requires transferring of coenzyme, acetyl-CoA to choline by a polarized mitochondrial membrane

electron transporting complexes, besides, the external supply of choline precursors such as pyruvate was sufficient to induce flow-evoked ACh production [69].

Scavenger receptor class B type I and vitamin D endothelial receptor

More recently, new investigations have addressed, scavenger receptor class B type I is an extremely important endothelial receptor, involved in the regulation of HDL transport in the liver, and its dysregulation is believed to be responsible for dyslipidemia and atherosclerosis development [70]. Furthermore, recent investigations were showing that the vitamin D endothelial receptor is directly involved in vasoactivity regulation, particularly in cerebral vessels, where the knockdown of the endothelial vitamin D receptor gene was accompanied by severe vasospasm [71].

Additionally, a small, highly conserved, intracellular calcium-binding protein termed CaM present in the EC. CaM regulates intracellular calcium influx, involved in several physiopathological processes including inflammatory and EC migration inhibition. CaM is required to activate transient receptor potential 6 (TRPC6) channels that later activate the TRPC5 channels to enhance intracellular calcium influx [72]. Also, CaM is involved in the leukocyte par-endothelial migration (TEM) via activating the IQ-domain GTPase-activating protein 1 (IQGAP1) and particularly CaM-binding isoleucine-glutamine (IQ), inhibition of CaM, theoretically can be used as an anti-inflammatory approach (Table 2) [73].

Differences between lymphatic EC and blood EC

A bunch of fundamental biological distinctions is present between the lymphatic and blood EC despite the topographical similarities, more than 400 differences in the expressed genes, returned to the difference in the functions of each (Table 3) [78]. The lymphatic EC perform a semi-professional antigen-presenting to the lymphatic circulatory T cytotoxic CD8 cells through invadosome-like protrusion (MHC-I) and express specific surface antigens and receptors such as podoplanin, VEGFR-3, or lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) [79, 80].

Remarkable evidence concluded that sigma receptor-1 of the lymphatic EC is responsible for the regulation of the tone and barrier function as well as the permeability of the lymphatic tree through regulation of nitroxide biosynthesis signaling pathway [20].

Table 3. Similarities and differences between the VEC and LEC

Common features	VEC	LEC
Barrier function, vasomotor tone, permeability, tissue vascularization, and immune response	Coagulation regulation Peroxisome proliferator-activated receptor delta H2S	Semi-professional antigen-presenting, B-cell homing to lymph nodes via CXCL13 expression
Surface receptor:	Surface receptor:	Surface receptor:
G-coupled-protein receptor, toll-like receptors (TLR 4), NOD-like receptor (NLR), IL-10 receptor, sphingosine-1-phosphate, and prostaglandins receptors, transient receptor potential, ephrin A, ephrin B2, and EphB4, neuropilins (accessory), Acetylcholine receptor (M1-5), Endoglin, scavenger receptors; CD36 (SR-B2) and SCARF-1 (SR-F1),	endothelial FcRn receptors, VEGFR-2, vascular endothelial protein tyrosine phosphatase receptor, vascular endothelial growth factor Flk1 receptor, sphingosine-1-phosphate receptor 1, NLRP6, TGF- β receptor, Thromboxane A2 receptor, angiotensin II receptor (AT1), scavenger receptor class B type I, G protein-coupled receptor 68, histamine receptor (H1), tyrosine kinase Tie2 bradykinin receptor (B2), vitamin D endothelial receptor, albondin (gp60), FGFR2, serotonin receptor (51), ET-1 receptor (ET-B), ADP and ATP receptor, DCC/neogenin and UNC5 receptors of netrin-1, Natriuretic peptide receptor A, B, and C	Vascular endothelial growth factor receptor-3 (VEGFR-3), IL-1, IL12, IL18, IL27 receptors, C-type lectin receptor, Fc receptor (FCGR2B), Lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), sigma receptor-1, Natriuretic peptide receptor D, scavenger receptors; MSR-1 (SR-A1), MARCO (SR-A6), STAB-2 (SR-H2), and CXCL16 (SR-G1)
Released molecules: endothelin, prostacyclin I2, nitric oxide, urotensin, CNP, adenosine, purines, reactive oxygen species, H2S		
Induce angiogenesis by CD112 (nectin-2), netrin-1, FGF-2, TGF- β , TNF- α , IGF-1, and VEGF	Released molecules: protein c and s, thrombomodulin, calmodulin, tissue-type plasminogen activator, plasminogen activator inhibitor type-I, platelet-activating factor, Von Willebrand factor, adrenomedullin	MAFB transcription factor overexpressed
MHC-II, H-2DM α , and H-2DM β overexpression 400 differences in the expressed genes	208 differences in the expressed genes (NRCAM, TAGLN, CD44, FSTL1, IL8, AUTS2, CXCL1, RNASE1, LTBP2, MCAM, AXL, DSG1, CAP2, ITGA5, ZNF207, FAP, ITGA4, PLA2G4A, BMP6, VAMP8, ACTA2, GPR39, ISG15, VCAN, RGS5, KRT7, COL6A3, DKK1, CXCR4, SEC, 61B, LPHN2, IL13RA2, IFI27, SRGN, GLIPR1, SELP, FBLN5, IL4R, SH3BP4, TPM2, BMP1, FLT1, EMP3, SERPINE1, CSF2RB, PCDH1, TSPAN3, IGF2BP3, ITGB3, VEGFC, HOXB, PLAU, vWF, CDH2, JAM3, PFN2, F2R, COL1A2, NCL, CHST1, ESM1, PGF, RP3-523C21.1, MMP1, EFEMP2, CCL2, CCT5, BASP1, CD93, C17orf72, ICAM2, SHISA3, MLT11, SPARC, ITGB5, MCTP1, CLU, LAMC1, LAMB2, CCRL2, GATA6, TGFBI, PECAM1, COL6A1, Clorf54, IL6, FN 1, TRIM22, LAMB1)	155 differences in the expressed genes (PROX-1, GMFG, CEACAM1, CXCL12, PVRL3, RBP1, F2RL1, PDPN, FABP4, MRC1, MRC1L1, TNFSF10, MAF, LGALS8, RELN, PPARG, CALCRL, HSD17B2, CH25H, PSMG1, MGP, TFF3, CD36, SEPP1, CCL5, ANGPT2, ID1, SLC26A4, JUP, DSP, SNRNP48, ADRB1, RGS16, GLRB, NID1, ITGA9, THBS1, LAYN, CDKN1C, HMMR, ADAMTSL3, CRMP1, IL6ST, SNAI2, PCSK6, JAG1, EPS8, ITGA1, CCL20, AK5, MEF2C, TGFA, RP11-65D13.1, APOD, FGF12, FDFIT1, PDLIM3, ITGA6, GRAMD3, CCNE2, MFAP3, COLEC12, TIMP3, GHR, CD200, HEY1, ADD3, GYPC, TK1, TFPI, LIPA)

VEC, vascular endothelial cells; LEC, lymphatic endothelial cells; vWF, von Willebrand factor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor. Source from [78, 81-87].

Conclusion

Progressive studies in the few previous years established remarkable advances in the molecular biopathology of EC physiopathology. Noticeably, EC present a high degree of heterogeneity in the expression of surface markers (>100 receptors), carrier proteins, and intracellular enzymes, across and within tissues [26]. Hence, EC contribute to maintaining

vascular homeostasis as well as regulate organ regeneration capacity after injury [88, 89]. Hypothetically, impaired organs, due to whatever trauma, regenerate only after normalizing blood supply and drainage. Therefore, by applying this concept, EC are directly involved in the recovery of damaged organs. This hypothesis impended the basis for regenerative medicine. Whenever required to enhance the organ's physiological performance, firstly, it is sufficient to normalize

blood circulation, while this required new vessel formation (angiogenesis). Thus, the investigated data emphasizes the endothelial role in the regulation of vital homeostatic metabolic activities.

EC function is influenced by tetrahydrobiopterin (BH₄), sex hormones and gender, angiotensin, insulin, vascular endothelial growth factor, physical and psychological stress, vitamin D, adiponectin, uric acid, lipids, oxygen-derived free radicals, aldosterone, and epithelial sodium channels. Probably, perturbation of plasma level of these factors indicates a pre-endothelial dysfunction stage and acts as a clinical marker that usually arises after the failure of the organism to correct/maintain or eliminate the pathological changes in the endothelial influencing factors. The current hypothesis, endothelial function is regulated by the crosstalk between the NO, adrenergic receptors, and oxidative stress. Where, oxidative stress impairs the NO bioavailability via a reduction in the synthesis pathway of the NO and adrenergic effect exerted by NO-dependent manner, while NO plays the central role in the regulation mechanisms. Targeting C-type natriuretic peptide is of great value in inducing angiogenesis [90].

ORCID

Basheer Abdullah Marzoog:
<https://orcid.org/0000-0001-5507-2413>

Author Contributions

Conceptualization: BAM. Data acquisition: BAM. Data analysis or interpretation: BAM. Drafting of the manuscript: BAM. Critical revision of the manuscript: BAM. Approval of the final version of the manuscript: all authors.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Funding

None.

References

1. Bierhansl L, Conradi LC, Treps L, Dewerchin M, Carmeliet P. Central role of metabolism in endothelial cell function and vascular disease. *Physiology* (Bethesda) 2017;32:126-40.
2. Khan S, Taverna F, Rohlenova K, Treps L, Geldhof V, de Rooij L, Sokol L, Pircher A, Conradi LC, Kalucka J, Schoonjans L, Eelen G, Dewerchin M, Karakach T, Li X, Goveia J, Carmeliet P. EndoDB: a database of endothelial cell transcriptomics data. *Nucleic Acids Res* 2019;47(D1):D736-44.
3. Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G, Nishigaki I. The vascular endothelium and human diseases. *Int J Biol Sci* 2013;9:1057-69.
4. Baselet B, Sonveaux P, Baatout S, Aerts A. Pathological effects of ionizing radiation: endothelial activation and dysfunction. *Cell Mol Life Sci* 2019;76:699-728.
5. Zhang J, Tecson KM, McCullough PA. Role of endothelial cell receptors in the context of SARS-CoV-2 infection (COVID-19). *Proc (Bayl Univ Med Cent)* 2021;34:262-8.
6. Félétou M. The endothelium: part 1: multiple functions of the endothelial cells-focus on endothelium-derived vasoactive mediators. *Colloq Ser Integr Syst Physiol* 2011;3:1-306.
7. Tian D, Teng X, Jin S, Chen Y, Xue H, Xiao L, Wu Y. Endogenous hydrogen sulfide improves vascular remodeling through PPAR δ /SOCS3 signaling. *J Adv Res* 2020;27:115-25.
8. Shuvaev VV, Brenner JS, Muzykantor VR. Targeted endothelial nanomedicine for common acute pathological conditions. *J Control Release* 2015;219:576-95.
9. Jambusaria A, Hong Z, Zhang L, Srivastava S, Jana A, Toth PT, Dai Y, Malik AB, Rehman J. Endothelial heterogeneity across distinct vascular beds during homeostasis and inflammation. *Elife* 2020;9:e51413.
10. Davies PF. Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. *Nat Clin Pract Cardiovasc Med* 2009;6:16-26.
11. Marzoog BA, Vlasova TI. The metabolic syndrome puzzles; possible pathogenesis and management. *Curr Diabetes Rev* 2022 Apr 29 [Epub]. <https://doi.org/10.2174/1573399818666220429100411>.
12. Marzoog BA. Recent advances in molecular biology of metabolic syndrome pathophysiology: endothelial dysfunction as a potential therapeutic target. *J Diabetes Metab Disord* 2022;21:1903-11.
13. Marzoog B. Lipid behavior in metabolic syndrome pathophysiology. *Curr Diabetes Rev* 2022;18:e150921196497.
14. Thakore P, Earley S. Transient receptor potential channels and endothelial cell calcium signaling. *Compr Physiol* 2019;9:1249-77.
15. Dalal PJ, Muller WA, Sullivan DP. Endothelial cell calcium signaling during barrier function and inflammation. *Am J Pathol* 2020;190:535-42.
16. Evans CE, Iruela-Arispe ML, Zhao YY. Mechanisms of endothelial regeneration and vascular repair and their application to

- regenerative medicine. *Am J Pathol* 2021;191:52-65.
17. Hu Y, Chen M, Wang M, Li X. Flow-mediated vasodilation through mechanosensitive G protein-coupled receptors in endothelial cells. *Trends Cardiovasc Med* 2022;32:61-70.
 18. Pernomian L, do Prado AF, Silva BR, de Paula TD, Grando MD, Bendhack LM. C-type natriuretic peptide-induced relaxation through cGMP-dependent protein kinase and SERCA activation is impaired in two kidney-one clip rat aorta. *Life Sci* 2021;272:119223.
 19. Wettschureck N, Strilic B, Offermanns S. Passing the vascular barrier: endothelial signaling processes controlling extravasation. *Physiol Rev* 2019;99:1467-525.
 20. Motawe ZY, Abdelmaboud SS, Breslin JW. Involvement of sigma receptor-1 in lymphatic endothelial barrier integrity and bioenergetic regulation. *Lymphat Res Biol* 2021;19:231-9.
 21. Frees A, Assersen KB, Jensen M, Hansen PBL, Vanhoutte PM, Madsen K, Federlein A, Lund L, Toft A, Jensen BL. Natriuretic peptides relax human intrarenal arteries through natriuretic peptide receptor type-A recapitulated by soluble guanylyl cyclase agonists. *Acta Physiol (Oxf)* 2021;231:e13565.
 22. Tao BB, Liu SY, Zhang CC, Fu W, Cai WJ, Wang Y, Shen Q, Wang MJ, Chen Y, Zhang LJ, Zhu YZ, Zhu YC. VEGFR2 functions as an H₂S-targeting receptor protein kinase with its novel Cys1045-Cys1024 disulfide bond serving as a specific molecular switch for hydrogen sulfide actions in vascular endothelial cells. *Antioxid Redox Signal* 2013;19:448-64.
 23. Xiao L, Dong JH, Teng X, Jin S, Xue HM, Liu SY, Guo Q, Shen W, Ni XC, Wu YM. Hydrogen sulfide improves endothelial dysfunction in hypertension by activating peroxisome proliferator-activated receptor delta/endothelial nitric oxide synthase signaling. *J Hypertens* 2018;36:651-65.
 24. Zuccolo E, Laforenza U, Negri S, Botta L, Berra-Romani R, Faris P, Scarpellino G, Forcaia G, Pellavio G, Sancini G, Moccia F. Muscarinic M5 receptors trigger acetylcholine-induced Ca²⁺ signals and nitric oxide release in human brain microvascular endothelial cells. *J Cell Physiol* 2019;234:4540-62.
 25. Berra-Romani R, Faris P, Pellavio G, Orgiu M, Negri S, Forcaia G, Var-Gaz-Guadarrama V, Garcia-Carrasco M, Botta L, Sancini G, Laforenza U, Moccia F. Histamine induces intracellular Ca²⁺ oscillations and nitric oxide release in endothelial cells from brain microvascular circulation. *J Cell Physiol* 2020;235:1515-30.
 26. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Res* 2018;46(D1):D1074-82.
 27. Tao BB, Cai WJ, Zhu YC. H₂S is a promoter of angiogenesis: identification of H₂S "receptors" and its molecular switches in vascular endothelial cells. *Handb Exp Pharmacol* 2015;230:137-52.
 28. Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ. Endothelin. *Pharmacol Rev* 2016;68:357-418.
 29. Maguire JJ, Davenport AP. Endothelin receptors and their antagonists. *Semin Nephrol* 2015;35:125-36.
 30. Kowalczyk A, Kleniewska P, Kolodziejczyk M, Skibska B, Goraca A. The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis. *Arch Immunol Ther Exp (Warsz)* 2015;63:41-52.
 31. Abdullah Marzoog B. Adaptive and compensatory mechanisms of the cardiovascular system and disease risk factors in young males and females. *New Emir Med J* 2023;4:e281122211293.
 32. Marzoog BA. Endothelial cell autophagy in the context of disease development. *Anat Cell Biol* 2022 Oct 21 [Epub]. <https://doi.org/10.5115/acb.22.098>.
 33. Motegi S. Endothelin. In: Takehara K, Fujimoto M, Kuwana M, editors. *Systemic Sclerosis*. Springer; 2016. p.155-71.
 34. Schiffrin EL. Does endothelin-1 raise or lower blood pressure in humans? *Nephron* 2018;139:47-50.
 35. Houde M, Desbiens L, D'Orléans-Juste P. Endothelin-1: biosynthesis, signaling and vasoreactivity. *Adv Pharmacol* 2016;77:143-75.
 36. Sousa J, Diniz C. Vascular sympathetic neurotransmission and endothelial dysfunction. In: Lenasi H, editor. *Endothelial Dysfunction*. IntechOpen; 2018.
 37. Conti V, Russomanno G, Corbi G, Izzo V, Vecchione C, Filippelli A. Adrenoreceptors and nitric oxide in the cardiovascular system. *Front Physiol* 2013;4:321.
 38. Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease - a 30th anniversary update. *Acta Physiol (Oxf)* 2017;219:22-96.
 39. Iring A, Jin YJ, Albarrán-Juárez J, Siragusa M, Wang S, Dancs PT, Nakayama A, Tonack S, Chen M, Künne C, Sokol AM, Günther S, Martínez A, Fleming I, Wettschureck N, Graumann J, Weinstein LS, Offermanns S. Shear stress-induced endothelial adrenomedullin signaling regulates vascular tone and blood pressure. *J Clin Invest* 2019;129:2775-91.
 40. Voors AA, Kremer D, Geven C, Ter Maaten JM, Struck J, Bergmann A, Pickkers P, Metra M, Mebazaa A, Düngen HD, Butler J. Adrenomedullin in heart failure: pathophysiology and therapeutic application. *Eur J Heart Fail* 2019;21:163-71.
 41. Li X, Sun X, Carmeliet P. Hallmarks of endothelial cell metabolism in health and disease. *Cell Metab* 2019;30:414-33.
 42. Vestweber D. Vascular endothelial protein tyrosine phosphatase regulates endothelial function. *Physiology (Bethesda)* 2021;36:84-93.
 43. Randi AM, Smith KE, Castaman G. von Willebrand factor regulation of blood vessel formation. *Blood* 2018;132:132-40.
 44. Nguyen TS, Lapidot T, Ruf W. Extravascular coagulation in hematopoietic stem and progenitor cell regulation. *Blood* 2018;132:123-31.
 45. Randi AM, Laffan MA. Von Willebrand factor and angiogenesis: basic and applied issues. *J Thromb Haemost* 2017;15:13-20.
 46. Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS, Papadopoulos N, Kyle AH, Minchinton AI, Yancopoulos GD, Thurston G. Angiopoietin-2 functions as a Tie2 agonist

- in tumor models, where it limits the effects of VEGF inhibition. *Cancer Res* 2013;73:108-18.
47. Funasaka T, Raz A, Nangia-Makker P. Galectin-3 in angiogenesis and metastasis. *Glycobiology* 2014;24:886-91.
 48. Kim SJ, Chun KH. Non-classical role of Galectin-3 in cancer progression: translocation to nucleus by carbohydrate-recognition independent manner. *BMB Rep* 2020;53:173-80.
 49. Groeneveld DJ, Sanders YV, Adelmeijer J, Mauser-Bunschoten EP, van der Bom JG, Cnossen MH, Fijnvandraat K, Laros-van Gorkom BAP, Meijer K, Lismann T, Eikenboom J, Leebeek FWG. Circulating angiogenic mediators in patients with moderate and severe von Willebrand disease: a multicentre cross-sectional study. *Thromb Haemost* 2018;118:152-60.
 50. Hepner M, Karlaftis V. Protein C. *Methods Mol Biol* 2013;992:365-72.
 51. Giri H, Cai X, Panicker SR, Biswas I, Rezaie AR. Thrombomodulin regulation of mitogen-activated protein kinases. *Int J Mol Sci* 2019;20:1851.
 52. Hepner M, Karlaftis V. Protein S. *Methods Mol Biol* 2013;992:373-81.
 53. Griffin JH, Zlokovic BV, Mosnier LO. Activated protein C, protease activated receptor 1, and neuroprotection. *Blood* 2018;132:159-69.
 54. Julovi SM, Shen K, Mckelvey K, Minhas N, March L, Jackson CJ. Activated protein C inhibits proliferation and tumor necrosis factor α -stimulated activation of p38, c-Jun NH2-terminal kinase (JNK) and Akt in rheumatoid synovial fibroblasts. *Mol Med* 2013;19:324-31.
 55. Healy LD, Puy C, Fernández JA, Mitrugno A, Keshari RS, Taku NA, Chu TT, Xu X, Gruber A, Lupu F, Griffin JH, McCarty OJT. Activated protein C inhibits neutrophil extracellular trap formation *in vitro* and activation *in vivo*. *J Biol Chem* 2017;292:8616-29.
 56. Loghmani H, Conway EM. Exploring traditional and nontraditional roles for thrombomodulin. *Blood* 2018;132:148-58.
 57. Ito T, Kakihana Y, Maruyama I. Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases. *Expert Opin Ther Targets* 2016;20:151-8.
 58. Pan B, Wang X, Nishioka C, Honda G, Yokoyama A, Zeng L, Xu K, Ikezoe T. G-protein coupled receptor 15 mediates angiogenesis and cytoprotective function of thrombomodulin. *Sci Rep* 2017;7:692.
 59. Son BK, Akishita M, Iijima K, Ogawa S, Arai T, Ishii H, Mae-mura K, Aburatani H, Eto M, Ouchi Y. Thrombomodulin, a novel molecule regulating inorganic phosphate-induced vascular smooth muscle cell calcification. *J Mol Cell Cardiol* 2013;56:72-80.
 60. Chen J, Chung DW. Inflammation, von Willebrand factor, and ADAMTS13. *Blood* 2018;132:141-7.
 61. Marzoug BA, Vlasova TI. Membrane lipids under norm and pathology. *Eur J Clin Exp Med* 2021;19:59-75.
 62. Heldin CH, Moustakas A. Signaling receptors for TGF- β family members. *Cold Spring Harb Perspect Biol* 2016;8:a022053.
 63. Xie X, Sun W, Wang J, Li X, Liu X, Liu N. Activation of thromboxane A2 receptors mediates endothelial dysfunction in diabetic mice. *Clin Exp Hypertens* 2017;39:312-8.
 64. Ellinsworth DC, Shukla N, Fleming I, Jeremy JY. Interactions between thromboxane A₂, thromboxane/prostaglandin (TP) receptors, and endothelium-derived hyperpolarization. *Cardiovasc Res* 2014;102:9-16.
 65. Ding J, Yu M, Jiang J, Luo Y, Zhang Q, Wang S, Yang F, Wang A, Wang L, Zhuang M, Wu S, Zhang Q, Xia Y, Lu D. Angiotensin II decreases endothelial nitric oxide synthase phosphorylation *via* AT₁R Nox/ROS/PP2A pathway. *Front Physiol* 2020;11:566410.
 66. Walker M, Green J, Ferrie R, Cook-Mills J. Serotonin receptor regulation of eosinophil transendothelial migration. *FASEB J* 2017;31:55.7.
 67. Saternos HC, Almarghalani DA, Gibson HM, Meqdad MA, Antypas RB, Lingireddy A, AbouAlaiwi WA. Distribution and function of the muscarinic receptor subtypes in the cardiovascular system. *Physiol Genomics* 2018;50:1-9.
 68. Radu BM, Osculati AMM, Suku E, Banciu A, Tsenov G, Merigo F, Di Chio M, Banciu DD, Tognoli C, Kacer P, Giorgetti A, Radu M, Bertini G, Fabene PF. All muscarinic acetylcholine receptors (M₁-M₅) are expressed in murine brain microvascular endothelium. *Sci Rep* 2017;7:5083.
 69. Wilson C, Lee MD, McCarron JG. Acetylcholine released by endothelial cells facilitates flow-mediated dilatation. *J Physiol* 2016;594:7267-307.
 70. Yu L, Dai Y, Mineo C. Novel functions of endothelial scavenger receptor class B Type I. *Curr Atheroscler Rep* 2021;23:6.
 71. Kashefiolas S, Leisegang MS, Helfinger V, Schürmann C, Pflüger-Müller B, Randriamboavonjy V, Vasconez AE, Carmeliet G, Badenhoop K, Hintereder G, Seifert V, Schröder K, Konczalla J, Brandes RP. Vitamin D-A new perspective in treatment of cerebral vasospasm. *Neurosurgery* 2021;88:674-85.
 72. Chaudhuri P, Rosenbaum MA, Sinharoy P, Damron DS, Birnbaumer L, Graham LM. Membrane translocation of TRPC6 channels and endothelial migration are regulated by calmodulin and PI3 kinase activation. *Proc Natl Acad Sci U S A* 2016;113:2110-5.
 73. Dalal PJ, Sullivan DP, Muller WA. Endothelial calmodulin and CaMKII play a role in leukocyte transmigration. *FASEB J* 2019;33:375.5.
 74. Shihoya W, Nishizawa T, Okuta A, Tani K, Dohmae N, Fujiyoshi Y, Nureki O, Doi T. Activation mechanism of endothelin ETB receptor by endothelin-1. *Nature* 2016;537:363-8.
 75. Xu S, Wen H, Jiang H. Urotensin II promotes the proliferation of endothelial progenitor cells through p38 and p44/42 MAPK activation. *Mol Med Rep* 2012;6:197-200.
 76. Ashraf MA, Nookala V. Biochemistry of platelet activating factor. *StatPearls*. Treasure Island: StatPearls Publishing; 2022.
 77. Ralevic V, Dunn WR. Purinergic transmission in blood vessels. *Auton Neurosci* 2015;191:48-66.
 78. Berendam SJ, Koepfel AF, Godfrey NR, Rouhani SJ, Woods AN, Rodriguez AB, Peske JD, Cummings KL, Turner SD, Engelhard VH. Comparative transcriptomic analysis identifies

- a range of immunologically related functional elaborations of lymph node associated lymphatic and blood endothelial cells. *Front Immunol* 2019;10:816.
79. Carman CV, Martinelli R. Lymphocyte-endothelial interactions. In: Bradshaw RA, Stahl PD, editors. *Encyclopedia of Cell Biology*. Elsevier; 2016. p.632-49.
 80. Ribatti D. The origins of lymphatic vessels: an historical review. In: Ribatti D, editor. *Milestones in Immunology*. Elsevier; 2017. p.129-62.
 81. Keuschnigg J, Karinen S, Auvinen K, Irjala H, Mpindi JP, Kallioniemi O, Hautaniemi S, Jalkanen S, Salmi M. Plasticity of blood- and lymphatic endothelial cells and marker identification. *PLoS One* 2013;8:e74293.
 82. Yang J, Zhang S, Zhang L, Xie X, Wang H, Jie Z, Gu M, Yang JY, Cheng X, Sun SC. Lymphatic endothelial cells regulate B-cell homing to lymph nodes via a NIK-dependent mechanism. *Cell Mol Immunol* 2019;16:165-77.
 83. Russo E, Runge P, Jahromi NH, Naboth H, Landtwing A, Montecchi R, Leicht N, Hunter MC, Takai Y, Halin C. CD112 regulates angiogenesis and T cell entry into the spleen. *Cells* 2021;10:169.
 84. Claro V, Ferro A. Netrin-1: focus on its role in cardiovascular physiology and atherosclerosis. *JRSM Cardiovasc Dis* 2020;9:2048004020959574.
 85. Dieterich LC, Tacconi C, Menzi F, Proulx ST, Kapaklikaya K, Hamada M, Takahashi S, Detmar M. Lymphatic MAFB regulates vascular patterning during developmental and pathological lymphangiogenesis. *Angiogenesis* 2020;23:411-23.
 86. Jourde-Chiche N, Fakhouri F, Dou L, Bellien J, Burtay S, Frimat M, Jarrot PA, Kaplanski G, Le Quintrec M, Pernin V, Rigotherier C, Sallée M, Fremeaux-Bacchi V, Guerrot D, Roumenina LT. Endothelium structure and function in kidney health and disease. *Nat Rev Nephrol* 2019;15:87-108.
 87. Becker PW, Sacilotto N, Nornes S, Neal A, Thomas MO, Liu K, Preece C, Ratnayaka I, Davies B, Bou-Gharios G, De Val S. An intronic Flk1 enhancer directs arterial-specific expression via RBPJ-mediated venous repression. *Arterioscler Thromb Vasc Biol* 2016;36:1209-19.
 88. Marzoog BA. Systemic and local hypothermia in the context of cell regeneration. *Cryo Letters* 2022;43:66-73.
 89. Marzoog BA, Vlasova TI. Myocardocyte autophagy in the context of myocardocytes regeneration: a potential novel therapeutic strategy. *Egypt J Med Hum Genet* 2022;23:41.
 90. Bubb KJ, Aubdool AA, Moyes AJ, Lewis S, Drayton JP, Tang O, Mehta V, Zachary IC, Abraham DJ, Tsui J, Hobbs AJ. Endothelial C-type natriuretic peptide is a critical regulator of angiogenesis and vascular remodeling. *Circulation* 2019;139:1612-28.